News Conference News AHA 2024 First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2 Caitlin E. Cox November 16, 2024
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2022 Botulinum Toxin Injections No Help for Postoperative AF: NOVA Yael L. Maxwell November 07, 2022
News Conference News HRS 2021 Progestin OCs Triple CV Events in Women With Congenital Long QT Caitlin E. Cox July 30, 2021
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Conference News ESC Heart Failure 2019 Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis Shelley Wood May 26, 2019
News Conference News HRS 2019 Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib Todd Neale May 17, 2019
News Conference News EHRA 2019 Coping With CABANA: Despite Trial Flaws, A-fib Experts Say Lessons Have Been Learned Todd Neale March 26, 2019
News Conference News TCT 2018 OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients Todd Neale September 24, 2018
News Conference News HRS 2018 CABANA Misses Primary Endpoint, but Electrophysiologists See Support for Ablation Todd Neale May 10, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2017 RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest Yael L. Maxwell March 20, 2017
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016